Kornimate/medical-research-clean huggingface dataset:
quantification of fecal calprotectin concentration difference between infants aged under 4 months old suffering from functional gastrointestinal disorders (fgid) and infants aged under 4 months old free from disorders : a transversal case-control monocentric study

Conditions: Functional Gastrointestinal Disorders; Infant, Newborn, Diseases

Summary: there is a high prevalence of fgid among infants : 30 % for regurgitations, 20 % for colitis , 15 % for functional constipation.this represents a frequent motive for pediatrics consultation : 23 to 28 % of medical consultations in this population are consequent to gastrointestinal symptoms among infants aged under 4 months old. this can lead to numerous inappropriate or unrecommended medication prescriptions. currently, fecal calprotectin threshold are only validated by science societies for children aged 5 years old and more. this study aims to quantify the difference of fecal calprotectin between a population of infants for whom no fgid has been finally detected, and a population of infants for whom fgid have been detected during the gastro-pediatrics consultation, , in order to later determine wether it is possible to validate a threshold in a population of infants aged under 4 months old.


Eligibility criteria:
inclusion criteria: * infants aged under 4 months old benefiting from a special gastro-pediatrics consultation * fgid arm : infant with one or several fgid detected * free from fgid arm : infant without any fgid detected exclusion criteria: * born before 37 week of amenorrhea. * neurologic failure, heart failure, respiratory failure, hepatic failure, pancreatic failure, renal failure, cancer or hematological malignancy. * history of enteral feeding by tube (nasogastric, nasojejunal, gastrostomy, gastrostomy-jejunostomy, jejunostomy) or parenteral feeding. * history of digestive tract surgery * suspicion of immunoglobulin e-mediated cow's milk protein allergy (cmpa): anaphylactic-type reaction observed within a few minutes to 2 hours after ingestion of cow's milk protein, such as pruritus, erythema, angioedema, intense abdominal pain, projectile vomiting, acute diarrhea, bronchospasm, faintness, loss of consciousness, arterial hypotension or even anaphylactic shock.
fecal microbiota transplantation for ulcerative colitis through colonic transendoscopic enteral tubing

Conditions: Ulcerative Colitis

Summary: to indicate the efficacy of fecal microbiota transplantation (fmt) for the treatment of ulcerative colitis (uc), the investigators design a multicenter, randomized controlled trial to perform fmt through colonic transendoscopic enteral tubing (tet) way, and evaluate the efficacy and safety of fmt for patients with moderate or severe uc.

1. patients with moderate to severe uc will be screened (mayo\>6）. 2. participants will be divided into control and study groups by double blind. 3. control group and study group will receive a colonic endoscopy evaluation. and a tet tube will be fixed at ileocecum. 4. enema with 5-asa 4g/day for 7days by tet will be performed as basic therapy for both control and study group. study and control group will be given with fecal microbiota suspension and equal volume of saline by tet for three times every other day in one week. 5. the follow-up will be performed at 1 week, 4 weeks and 12 weeks after first treatment. all the participants will receive a endoscopy evaluation at 12 weeks. clinical remission, clinical improvement and safety are the primary endpoint at 12 weeks; intestinal microbiota changing is recognized as the secondary endpoint.

Eligibility criteria:
inclusion criteria: * active, moderate to severe severity (mayo score more than 6) * safety using history of 5-asa. * able to undergo endoscopy examination. exclusion criteria: * immunosuppressive drugs and glucocorticoids using in 4 weeks * antibiotic using in 7 days * high risk of toxic megacolon * colon cancer or neoplasia in pathophysiology * other severe diseases (eg: cardiovascular, respiratory, gastroenteral and kidney diseases)

Keywords: fecal microbiota transplantation ulcerative colitis
percutaneous nephroscopic treatment of parapelvic cysts

Conditions: Kidney Stone; Parapelvic Cyst; Kidney Diseases; Recurrence

Summary: background of the project: the surgical treatment of parapelvic cysts is currently less researched and there is no gold standard for surgery. previously, in percutaneous nephrolithotomy, we found that fenestration and fenestration drainage in the simultaneous treatment of pararenal pelvis cysts under nephroscopic nephroscopic surgery has clear curative effect, less trauma, and quicker recovery. objective: to clarify the safety, efficacy and long-term efficacy of percutaneous nephroscopy in the treatment of parapelvic cysts. nature: retrospective case cohort study. basic research process: retrospective collection of cases in our hospital who underwent percutaneous nephroscopy for the treatment of parapelvic cysts, and comparison of preoperative and postoperative cyst size changes and long-term efficacy.


Eligibility criteria:
inclusion criteria: * age 18 or older * has undergone percutaneous nephroscopic surgery for parapelvic cysts * ability to receive study follow-up exclusion criteria: * patient refuses or is unable to give consent

Keywords: parapelvic cyst recurrence kidney diseases
study evaluating the laser diode effect burning mouth syndrome

Conditions: Burning Mouth Syndrome

Summary: the aim of this study was to report the effect of laser diode on the treatment of burning mouth syndrome (bms) patients were randomly allocated to two different groups: the first one (group a) underwent laser diode whereas the second one (group b) received laser diode inactive

the inclusion criteria were as follows: (a) oral burning sensation, at least in the last 6 months; (b) no detection of oral mucosal lesions; and (c) ability to complete the present clinical trial. the exclusion criteria were as follows: (a) diagnosis of sjögren syndrome on the basis of european criteria ; (b) previous head and neck radiotherapy; (c) diagnosed lymphoma; (d) hepatitis c infection; (c) pregnant or breast-feeding women

Eligibility criteria:
inclusion criteria: * diagnosis of burning mouth syndrome in accordance the international classification of headaches: continuous symptoms of oral burning or pain on a daily or almost daily basis, during all or part of the day for more than 6 months exclusion criteria: * history of head and neck malignancy, radiation therapy to the head and neck area, poorly managed diabetes mellitus, chronic thyroid disease, or known sjogren's disease and pregnant

Keywords: laser diode, pain
healthcare resource utilisation, common mental health problems, and infections in people with inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases; Ulcerative Colitis; Crohn Disease

Summary: ulcerative colitis and crohn's disease are the commonest types of inflammatory bowel disease (ibd). both conditions range in severity from no symptoms to being potentially fatal. both conditions are treated with medications which suppress the immune system. it is not known whether this increases the risk for infections and cancers in these conditions. it is also recognised by healthcare professionals that these conditions cause a considerable amount of psychological distress. however, this has never been measured in a large population sample. this study will investigate any associations with treatment and new onset infections and cancer. they will also examine the relationship between ibd and common mental health problems (specifically, depression and anxiety) and the impact that these have on the healthcare use (including number of general practitioner \[gp\] appointments, hospital attendances, and medication prescriptions. combined, these studies should provide a better understanding of the impact of ibd on affected people and provide evidence to support the correct allocation of healthcare resources.

objective we aim to provide an accurate and contemporary measurement of the current healthcare resource utilisation in people with inflammatory bowel disease (ibd); namely ulcerative colitis (uc) and crohn's disease (cd). we also aim to provide estimates of infection incidence in this population and the prevalence of common mental health conditions. method we will identify uc and cd using algorithms validated for accurately identifying these conditions from primary care records in the united kingdom (uk). we will identify a prevalent cohort of adults with ibd with the royal college of general practitioners (rcgp) research and surveillance centre (rsc) network over the last decade. we will identify a matched cohort of people without ibd; matched on age, gender and primary care practice. across these cohorts we will compare healthcare resource utilisation (primary care attendances, number of primary care prescriptions for antidepressant and anxiolytic medications, number of primary care prescriptions for medications used in ibd, recorded secondary care attendances, and issue of statements of fitness for work), incident infections (any common infection, any viral infection, or any gastrointestinal infection), and common mental health conditions (depression and anxiety).

Eligibility criteria:
inclusion criteria: * patients aged ≥18 years over the study period * registered with a contributing primary care practice for any duration during the study period exclusion criteria: * ibd not classifiable or of a type other than uc or crohn's disease
brca1/2 and effect of mifepristone on the breast

Conditions: Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2

Summary: ovarian steroids, as well as their synthetic counterparts gestagens and estrogens have a role in breast cell proliferation and the development of breast cancer. here, the effect of a progesterone receptor modulator, mifepristone, on cell proliferation in human breast tissue in vivo will be studied in women with brca-1 or -2 mutations. our preliminary results implicate a possible protective effect of mifepristone in breast epithelium. the ability of mifepristone to block breast epithelial cell proliferation may prevent tumorigenesis and may also prove beneficial when used for contraceptive purposes and on other indications. the proposed project concerns a randomized controlled trial on mifepristone versus placebo treatment of women with brca-1or -2 mutations with a high risk/incidence of breast cancer and ovarian cancer.

objectives • research objective to study the safety and effect of treatment with mifepristone, a progesterone receptor modulator, on epithelial cell proliferation in human breast tissue in women with brca-1 or -2 mutations prior to protective mastectomy. project description • hypothesis/ theory mifepristone treatment exerts an antiproliferative, protective effect on breast tissue in women with brca-1 or -2 mutations study design randomized, double blind, placebo controlled trial. women will be recruited among patients with brca-1 or -2 mutations scheduled for prophylactic mastectomy. included women will be randomized to a 3-month treatment with mifepristone, 50 mg (mifegyne, exelgyn, paris, france) or placebo taken orally every second day. breast biopsies will be obtained in the luteal phase prior to start of treatment and again during surgery.

Eligibility criteria:
inclusion criteria: * pre-menopausal women, \>/= 18 years of age * with good general health and * regular menstrual cycles (25-35 days) who are willing and * able to participate after giving informed consent. * women having brca1/2 mutation and have decided to undergo risk reducing mastectomy exclusion criteria includes: * any hormonal treatment used within 2 months prior to study start and * any contraindication to mifepristone
safety and tolerability of low-dose temozolomide during whole brain radiation in patients with cerebral metastases from non-small-cell lung cancer (study p04071)(terminated)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is a phase ii, randomized, multicenter, open-label study designed to assess the safety and tolerability of concomitant chemotherapy with low-dose temozolomide during whole brain radiation and later on at 14 days on/14 days off schedule in patients with cerebral metastases from non-small cell lung cancer (nsclc). the response to temozolomide will be evaluated by clinical follow up and magnetic resonance imaging (mri) performed every 2 months. progression-free survival at 6 months, duration of overall survival, and quality of life will also be evaluated.


Eligibility criteria:
inclusion criteria: * prior histologic confirmation of non-small cell lung cancer (nsclc). * optional: nsclc histologic confirmation of metastasis of nsclc. * presence of unidimensionally measurable disease in the brain. * no previous or current malignancies at other sites with the exception of adequately treated in situ carcinoma of the cervix or basal and squamous carcinoma of the skin. * age: \>18 years. * subjects must not have systemic disease that in the opinion of the investigator is in immediate need of chemotherapy * karnofsky performance status \>=70%. * absolute neutrophil count (anc) \>1,500/mm\^3, platelets \>100,000/mm\^3, hemoglobin \>8 g/dl. * serum creatinine and bilirubin \<1.5 times upper normal limit of testing laboratory. * serum glutamic oxaloacetic transaminase (sgot), serum glutamic pyruvic transaminase (sgpt) \<3 times upper limit of testing laboratory. * palliative radiation therapy to thorax and bone or other organs (except brain) is acceptable. * prior neurosurgery \>2 weeks from initiating treatment with temozolomide. * cortisone medication stable or decreasing within 2 weeks prior to initiating treatment with temozolomide. * patient is not pregnant or nursing and is advised and willing to use an effective method of contraception. * written informed consent. exclusion criteria: * chemotherapy or biologic therapy within four weeks prior to initiating therapy with temozolomide. * prior radiation therapy for brain \<4 weeks from initiating therapy with temozolomide. * surgery within two weeks prior to temozolomide administration. * recursive partitioning analysis (rpa) class iii * patients with a single brain metastasis amenable to radiosurgery of resection * known human immunodeficiency virus (hiv) disease. * acute infection requiring intravenous antibiotics. * any reason making compliance to the protocol improbable.

Keywords: temozolomide radiotherapy
incidence, risk factors and impact of significant pain in patients undergoing neurosurgery

Conditions: Postoperative Pain; Neurosurgery

Summary: the proposed study intends to evaluate incidence of postoperative pain after neurosurgery. this study is likely to help in understanding of the magnitude of this problem in our country and inform about possible predictors which will help institute pre-emptive interventions to mitigate modifiable risk factors of pain after neurosurgery.

data regarding potential risk factors for postoperative pain will be collected. preoperative factors (preoperative pain, anxiety or depression, perception about surgery, age, gender, socio-economic status, educational level, domicile location, obesity, surgical site \[infratentorial or supratentorial or cervical, thoracic or lumbar\], use of steroids and analgesics), and intraoperative factors (scalp/esp/caudal block, incision site infiltration, dose of analgesics such as opioids, paracetamol and non-steroidal anti-inflammatory drugs (nsaids), co-analgesics such as nitrous oxide, gabapentionoids, dexmedetomidine, magnesium or lignocaine infusion, anti-epileptics, steroids, minimum alveolar concentration (mac) of inhalational anesthetics, and duration of surgery and anesthesia) that are likely to be associated with occurrence of postoperative pain will be explored along with relationship between acute and persistent postoperative pain and between intraoperative nociception and postoperative pain.

Eligibility criteria:
inclusion criteria: * all eligible consecutive consenting adult patients aged \> 18 years with preoperative glasgow coma scale (gcs) score of 15 undergoing elective craniotomies and spine surgeries exclusion criteria: * children, patients with gcs \< 15, patients not extubated within 2 hours of end of anesthesia and those who not able to respond to our questions on outcomes
pre-calculated doses of medication for pediatric resuscitation, a simulation experimental trial

Conditions: Healthy

Summary: dosage errors are common in the stressful situation of a pediatric resuscitation. in addition to that, studies have reported that delays to provide medication is associated to worst survival rate for very sick children. to minimize delays and error, the investigators recently published a resuscitation handbook who provides drug dosages for each weight for children thus eliminating the need for dosage calculation. once the weight of the patient is known, the physicians only have to open the book at the page corresponding to the weight and all the medications with their calculated dosage are provided. the primary goal of this study is to evaluate the number of dosage error during simulated pediatric resuscitation comparing residents using the handbook vs. utilisation of a chart providing non-calculated dosage. this will be an experimental crossover trial among 40 residents performing four simulated case-scenarios in a high-fidelity simulation lab.


Eligibility criteria:
inclusion criteria: * residents doing a rotation in pediatrics emergency medicine exclusion criteria: * resident who participated in a previous month

Keywords: children resuscitation simulation medication error
diagnostic performance of non-endorectal coil multiparametric magnetic resonance imaging of prostate with flexible air coil (donemac study)

Conditions: Prostate Cancer

Summary: multiparametric mri (mpmri) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (cspca) in men with an elevated serum prostate specific antigen, which can decrease the rate of unnecessary biopsies and reduce the incidence of over-diagnosis of non-cspca. furthermore, there is evidence that mri is more accurate in detecting high-grade (gleason grade group ≥3) versus low grade cancers (gleason grade group \<2) and therefore may serve as a useful adjunct to prostate-specific antigen (psa) testing, digital rectal examination, and prostatic biopsy to detect cancers that require definitive treatment as opposed to active surveillance. many investigators, including our group, have shown the utility of preoperative mpmri to assess the local extent of prostate cancer and for surgical planning.

primary objective: to compare the detection rate of gleason group grade ≥ 2 disease in patients with intermediate and high-risk prostate cancer who undergo erc mpmri (group 1: control) versus patients who undergo non-erc mpmri with flexible air coil technology (group 2: experimental). secondary objective: 1. to compare the scanning time and room time in group 1 versus group 2. 2. to compare patient-reported outcome at the end of the mri test in group 1 versus group 2 through testing morbidities index (tmi). 3. to determine the impact of mpmri on treatment planning for men with intermediate and high-risk prostate cancer and compare management impact in group 1 versus group 2 4. to compare the detection rate of t3 disease on mri (confirmed by histopathology) at prostatectomy between group 1 versus group 2.

Eligibility criteria:
inclusion criteria: * male, age ≥ 18 * untreated, biopsy-proven with intermediate and high-risk (gleason group grade \>/=2) adenocarcinoma of the prostate * patient is being considered for curative-intent treatment with radical prostatectomy within 6 months following mpmri * patient has provided written informed consent for participation in this trial * patient should be eligible for scanning at 3 t magnet exclusion criteria: * low-risk adenocarcinoma of prostate * patient has had any prior therapy for prostate cancer * a history of other active malignancy within the last 2 years * prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components * cardiac pacemaker * orthopedic hardware in the pelvis and spine. * claustrophobia and/or receiving anesthesia * contraindication for endorectal coil such as rectal bleeding, severe anal fissures or hemorrhoids, anal/rectal surgery, and lack of rectum.
reduced visit frequency in the treatment of uncomplicated severe acute malnutrition: evaluation of operational feasibility and safety

Conditions: Severe Acute Malnutrition

Summary: community-based management of severe acute malnutrition (sam) has been shown to be safe and cost-effective, but program coverage remains low. new treatment models that maintain high levels of clinical effectiveness but allow for increased coverage are still needed. a reduced schedule of follow-up, in which children receive clinical follow-up and therapeutic foods on a monthly rather than weekly or biweekly basis, may be one alternative. this study aims to describe the safety and feasibility of a monthly distribution of ready-to-use therapeutic food in the treatment of uncomplicated sam, in terms of clinical response to treatment and household ready-to-use therapeutic food (rutf) utilization. this is a non-randomized pilot intervention study in which 115 children eligible for the outpatient treatment of sam were provided a monthly ration of rutf. anthropometric measurements were taken on a weekly basis for 4 weeks to monitor treatment response defined as weight gain, (mid-upper arm circumference) muac gain, weight loss \> 5%, and the development of edema. unannounced household spot checks were conducted over 4 weeks to assess household utilization of rutf and storage practices.


Eligibility criteria:
inclusion criteria: * a) being eligible for new admission to treatment of uncomplicated sam * b) being resident within 15 km of the study health center exclusion criteria: * previously default from previous sam treatment (e.g. missed 2 consecutive weekly visits) * considered a relapse case (e.g. re-admitted within three months of previous discharge)
periodontal disease treatment of a physically challenged population

Conditions: Periodontal Disease

Summary: many physically handicapped patients at the dental department, toronto rehabilitation institute(tri) have considerable gingival inflammation and breath odour because of the inability to effectively handle a toothbrush. these patients have considerable periodontal disease. there is a concern that these pathogens may have a detrimental effect on wound healing in other areas of the body. hypothesis: patients attending the dental department at tri that are treated with the antibiotic-antifungal rinse containing metronidazole and nystatin will show substantial decrease in periodontal disease as measured by bleeding points and pocket depth when compared to the group that continues to use their regular oral hygiene methods (control group).


Eligibility criteria:
inclusion criteria: participants must be between the ages of 18 to 65 years participants must have at least 6 teeth. participants must have some indication of gingivitis and periodontal breakdown. - exclusion criteria: patients who are taking warfarin/coumadin patients who are allergic to metronidazole or chlorhexidine. edentulous patients will be excluded by those who have at least 6 teeth can be a participant -

Keywords: periodontal disease bleeding on probing periodontal pockets disabled